Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer

Shi Chen1,*, Run-Cong Nie2,*, Li-Ying OuYang3,*, Yuan-Fang Li2, Jun Xiang1, Zhi-Wei Zhou2, YingBo Chen2, JunSheng Peng1

1The 6th Affiliated Hospital, Sun Yat-Sen University, YuanCun ErHeng Road, TianHe District, 510655, Guangzhou, China
2Department of Gastropancreatic Surgery, Sun Yat-Sen University Cancer Center, 510060, Guangzhou, China
3Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, 510060, Guangzhou, China

*These authors contributed equally to this work

Correspondence to: Ying-Bo Chen, email: chenyb@sysucc.org.cn
Jun-Sheng Peng, email: pengjunsheng@tom.com

Keywords: gastric cancer, lymph node metastasis, risk, nomogram

Received: July 25, 2016 Accepted: December 27, 2016 Published: January 06, 2017

ABSTRACT

Aim: To identify risk factors for lymph node metastasis using a nomogram for gastric cancer patients to predict lymph node metastasis.

Results: The Chi-square test and the logistic regression showed that the Boarrmann type, preoperative CA199 level, T stage and N stage by CT scan were independent risk factors. The concordance index (C-index) was 0.786 in the internal validation of the Nomogram model. In the external validation, the C-index was 0.809, and the AUC was 0.894. The total accuracy of the prediction was 82.2%, and the false-negative rate was 5.4% with a cut-off value set at 0.109.

Materials and Methods: The study consisted of 451 patients with a histological diagnosis of gastric cancer with 0 or 1 lymph node metastasis from the Sun Yat-sen University Cancer Center as the development set, and the validation set consisted of 186 gastric cancer patients from the Sixth Affiliated Hospital of Sun Yat-Sen University. A Chi-square test and a logistic regression analysis were used to compare the clinicopathological variables and lymph node metastasis. The C-index and ROC curve were computed for comparisons of the nomogram’s predictive ability.

Conclusions: We developed and validated a nomogram to predict lymph node metastasis in gastric cancer before surgery. This nomogram can be broadly applied, even in general hospitals, and is useful for decisions regarding treatment programs for patients.

INTRODUCTION

Although the morbidity of gastric cancer continues to decline in North America and Western Europe, it remains the second most malignant tumor in China [1, 2]. D2 gastrectomy has now become the standard surgery for gastric cancer, especially advanced gastric cancer [3, 4]. However, with the development of screening, an increasing number of early stage gastric cancer cases are found. Because D2 gastrectomy commonly causes more postoperative complication and mortality, surgeons believe that endoscopic mucosa resection (EMR) is the best fit the early stage gastric cancer. However, lymph node metastasis is the most common metastatic path for gastric cancer, even in early stage gastric cancers. The prevalence of lymph node metastasis in early gastric cancer (EGC) is reported to be in the range of 7.7 to 19.4% [5–7]. If EMR is undertaken as a radical surgery in these early stage gastric cancer patients, it is difficult to avoid recurrence. Thus, precise predictions of lymph node metastasis are very important for gastric cancer patients, especially at the early stage.

Sentinel lymph nodes were first used to predict lymph node metastasis, and it has been proven to be
effective in malignant melanoma and breast cancer [8–10]. However, in gastric cancer, the drainage of the lymph node is net-style, which is more complicated than in melanoma and breast cancer. It is difficult for clinicians to accurately locate the sentinel lymph node, even with the development of nano lymph node tracers and \(^{99}\)mTc tin colloid [10, 11].

CT scan and ultrasound endoscopy are currently commonly used in the clinic to evaluate the preoperative staging of gastric cancer before surgery. The accuracy of these tools is still not satisfying, according to a report by Feng XY et al. The accuracy, regarding the presence of LM, was 61.1% in MSCT studies [12]. Indeed, it is very important to have a model to predict the risk of lymph node metastasis because an accurate prediction of lymph node metastasis is mandatory to reduce the extent of surgery without hampering the oncological safety of EGC patients.

Nomograms have been widely used for predicting the prognosis of malignant cancer patients and quantifying the risk factors of lymph node metastasis in breast cancer and prostate cancer [13–15]. The aim of the present study was to identify risk factors of lymph node metastasis using a nomogram for patients with gastric cancer to guide treatment management.

RESULTS

Correlations between lymph node metastasis and the clinicopathological features of gastric cancer patients with 0 or 1 lymph node metastasis in the SYSUCC group

Among the 451 gastric cancer patients, lymph node metastasis was associated with tumor size, Boarrrmann type, histological type, preoperative CEA and CA199 level, T stage and N stage by CT scan (all \(p < 0.05\)). The results are shown in Table 1.

The nomogram for the prediction of metastatic lymph nodes

We used a logistic regression model for the multiple variable analysis of the lymph node metastasis for gastric cancer. We observed that the Boarrrmann type, T stage evaluated by CT, N stage evaluated by the CT and the preoperative serum CA19-9 level were independent risk factors for lymph node metastasis in gastric cancer. The results are shown in Table 2.

Thus, we chose these four factors to develop a predictive nomogram for lymph node metastasis in gastric cancer patients. The nomogram corresponding to the model, including the possible factors that may increase the incidence of lymph node metastasis, is shown in Figure 1. The total score of each patient was calculated by the sum of the points determined by these four factors (Boarrrmann type, T stage evaluated by CT, N stage evaluated by the CT and the preoperative serum CA19-9 level). Furthermore, we developed an internal calibration curve to validate the Nomogram model and found that the C-index was 0.786. (Shown in Figure 2).

External validation of the nomogram model by the gastric cancer patients from the SYSUGIH

We used the 186 gastric cancer patients from the SYSUGIH to estimate the predictive accuracy of the model. We developed an ROC curve for these patients. In this external validation, the C-index was 0.809, and the AUC was 0.894. The total accuracy of the prediction was 82.2%, and the false-negative rate was 5.4% with a cut-off value set at 0.109. The results are shown in Figures 3 and 4.

DISCUSSION

Currently, clinicians often use the CT scan and the EUS to determine the N stage of the gastric cancer. However, the operative N stage of gastric cancer determined by CT scan and EUS were not satisfied. Previous studies showed that the accuracy of N stage by CT scan was 64–78% [13,16,17]; in addition, for EUS, the accuracy was also 50–71.2% [18–20]. It was still confusing for clinicians to identify the standard to determine whether the enlarged lymph node was a metastasis using CT or EUS. A length of more than 5 mm or 10 mm have both been used as the standard, but neither of these achieves the best effect in the preoperative staging of gastric cancer. PET-CT was also used in the preoperative judgement of lymph node metastasis and demonstrated its advantage on distant lymph node metastasis and bone metastasis [21]. However, the accuracy of PET-CT for regional lymph node metastasis did not demonstrate an advantage over CT or EUS [22]. In addition, it is not commonly accepted because of its radiation and expensive cost. Thus, we tried to obtain an accurate preoperative lymph node status by comprehensively considering the clinicopathological factors, including the tumor characteristics and its markers.

In our study, we used patients with a solitary lymph node metastasis and without lymph node metastasis to construct the model. We believed that patients with a solitary lymph node metastasis meant they were in the first or early step of lymph node metastasis. In our study, the cut-off value was set at 0.109, and under the validation, we found that the accuracy of the prediction of lymph node metastasis was 82.2%. In addition, the false-positive rate was 12.4%, and the false-negative rate was 5.4%. In the clinic, we know that approximately 10% of early stage gastric cancer patients will have lymph node metastasis, and we tried to ensure that they have the appropriate surgery with lymph node dissection but not ESD or EMR. In our study, the main purpose was to detect the existence of the lymph node metastasis to help surgeons make precise therapy decisions for the patients. A higher false-negative rate of the lymph node metastasis prediction and more EGC
patients would have lymph node recurrence after ESD or EMR. Thus, we can accept the 0.109 as the cut-off value to reduce the false-negative rate of the prediction.

Previous studies have commonly proposed submucosal invasion as a significant risk factor predicting LNM [7, 15, 23, 24] and implied that T stage is the independent risk factor for lymph node metastasis. In the clinic, doctors always use CT scan and endoscopic ultrasound to evaluate the T stage of gastric cancer before surgery. Although CT can acquire a greater advantage in the evaluation of T stage of gastric cancer in the pathological T3 and T4 stages, with an accuracy of approximately 89% to 98%, it was still difficult to differentiate the T1 and T2 gastric cancer. In Luo's study, for example, the results showed that the evaluation accuracy of pathological stages T1 and T2 for gastric cancer by spiral CT was approximately 42.86%. In general, the accuracy rates in recent studies using multi-detector row CT for T and N staging have been reported to be 71.4–88.9% and 64–78%, respectively [22–25].

In our study, Boarrmann classification was also an important factor to predict lymph node metastasis

Table 1: Correlation between solitary lymph node metastasis and clinicopathological variables in the development set

| Clinicopathological parameters | Development set (n = 451) | Validation set (n = 186) |
|--------------------------------|--------------------------|--------------------------|
|                                | lymph node metastasis    | lymph node metastasis    |
|                                | n  | Negative | Solitary | χ² | P value | n  | Negative | Positive | χ² | P value |
| All                            | 451 | 350 | 101 | 25.579 | < 0.001 | 186 | 59 | 127 | 21.038 | < 0.001 |
| Tumor size (cm)                |     |          |          |     |          |     |          |          |     |          |
| < 5                            | 288 | 248 | 44 | 96 | 45 | 51 | 60 | 14 | 76 | 52.902 | < 0.001 |
| ≥ 5                            | 163 | 102 | 57 | 90 | 14 | 76 | 56 | 14 | 76 | 78.276 | < 0.001 |
| Boarrmann type                 |     |          |          |     |          |     |          |          |     |          |
| I                              | 44  | 40  | 4  | 29 | 27 | 2  | 15 | 5  | 10 | 7.859 | 0.049 |
| II                             | 226 | 201 | 25 | 86 | 30 | 56 | 63 | 17 | 46 | 13.228 | 0.004 |
| III                            | 177 | 107 | 70 | 61 | 2  | 59 | 44 | 16 | 28 | 34.241 | < 0.001 |
| IV                             | 4   | 2   | 2  | 10 | 0  | 10 | 10 | 0  | 10 | 53.372 | < 0.001 |
| Histological Grade             |     |          |          |     |          |     |          |          |     |          |
| high-differentiated            | 24  | 23  | 1  | 13 | 10 | 3  | 12 | 7  | 5  | 7.086 | 0.008 |
| median-differentiated          | 143 | 116 | 27 | 52 | 15 | 37 | 53 | 13 | 40 | 11.484 | 0.001 |
| low-differentiated             | 230 | 169 | 61 | 102 | 29 | 73 | 88 | 22 | 66 | 23.56 | 0.167 |
| undifferentiated               | 54  | 42  | 12 | 19 | 5  | 14 | 21 | 3  | 18 | 7.598 | 0.006 |
| Tumor infiltration             |     |          |          |     |          |     |          |          |     |          |
| T1                             | 121 | 112 | 9  | 28 | 25 | 3  | 18 | 21 | 3  | 32.811 | < 0.001 |
| T2                             | 83  | 70  | 13 | 18 | 6  | 12 | 10 | 8  | 2  | 3.033 | 0.081 |
| T3                             | 14  | 7   | 7  | 99 | 23 | 76 | 21 | 8  | 13 | 34.510 | < 0.001 |
| T4a                            | 206 | 144 | 62 | 41 | 5  | 36 | 17 | 5  | 12 | 2.437 | 0.119 |
| T4b                            | 27  | 17  | 10 | 0  | 0  | 0  | 11 | 1  | 10 | 2.011 | 0.156 |
| Preoperative CEA               |     |          |          |     |          |     |          |          |     |          |
| Normal                         | 389 | 310 | 79 | 131 | 46 | 85 | 130 | 46 | 84 | 7.086 | 0.008 |
| Elevated                       | 62  | 40  | 22 | 55 | 13 | 42 | 65 | 16 | 49 | 2.356 | 0.167 |
| Preoperative CA19-9            |     |          |          |     |          |     |          |          |     |          |
| Normal                         | 351 | 281 | 70 | 148 | 54 | 94 | 120 | 43 | 77 | 11.484 | 0.001 |
| Elevated                       | 30  | 16  | 14 | 38 | 5  | 33 | 25 | 5  | 20 | 7.598 | 0.006 |
| N stage by CT scan             |     |          |          |     |          |     |          |          |     |          |
| Negative                       | 332 | 280 | 52 | 72 | 41 | 31 | 36 | 14 | 22 | 32.811 | < 0.001 |
| Positive                       | 119 | 114 | 18 | 96 | 38 | 58 | 58 | 14 | 44 | 34.510 | < 0.001 |

*Numbers of cases in each group. * Statistically significant (P < 0.05).
before the surgery. We used the CT scan and endoscopy to observe the shape of the tumor to determine the preoperative Boarrmann classification of the patients. As we know, Boarrmann III and IV type gastric cancer always mean more invasiveness than the Boarrmann I and II type patients, and more invasiveness means an increased possibility of lymph node metastasis.

Actually, several nomograms were built to predict the lymph node status for gastric cancer. The purpose of our research was to select gastric cancer patients to undergo ESD or EMR precisely. In our study, we used a special group of gastric cancer patients who has a solitary lymph node metastasis or without lymph node metastasis to develop the nomogram model. We believe this model will have a high sensitivity for predicting lymph node metastasis in gastric cancer patients. As shown in our validation, the total accuracy of the validation group was 82.2%, with a false-negative rate of 5.4%. In addition, in our model, we only use 4 factors, which are easy to examine in the clinic to predict lymph node metastasis.

In 2014, The Cancer Genome Atlas (TCGA) network classified gastric cancer into the following four subtypes: Epstein-Barr virus (EBV)-positive tumors, microsatellite instable (MSI) tumors, gnomically stable (GS) tumors, and tumors with chromosomal instability (CIN) [23, 24]. A deep understanding of GC molecular characterizations has led to new therapeutic strategies, which may also help us to understand the molecular mechanism of lymph node metastasis in gastric cancer. We hypothesized that the gastric cancer patients with some special molecular characteristics might have the potential characteristics to promote lymph node metastasis. This molecular classification would help clinicians to predict lymph node metastasis based on the clinicopathological factors.

However, our study has several limitations. First, endoscopic ultrasound has been commonly used in the clinic to evaluate the stage of gastric cancer before surgery. However, our model group included patients from 2000 to 2012. In the early years, EUS was not widely used on these GC patients. Thus, we did not include the T and N stage evaluated by EUS in the nomogram model. Second, this study was a two centers, and the validation group has only 186 patients. We need more data to validate the model. Finally, we used the existence of lymph node metastasis as our primary goal, but the rate of lymph node metastasis of GC causes more and more concerns in

| Table 2: Multivariate analyses of the lymph node metastasis in the development set (Logistic regression model) |
|---------------------------------------------------------------|
| **Variable** | **OR** | **95% CI** | **P value** |
| Lymph node metastasis risk in gastric cancer patients | 0.911 | 0.469–1.770 | 0.784 |
| **Histological grade** | | | 0.548 |
| high-differentiated | Ref | Ref | |
| median-differentiated | 0.530 | 0.052–5.440 | |
| low-differentiated | 0.691 | 0.232–2.053 | |
| undifferentiated | 1.132 | 0.428–2.992 | |
| **Boarrmann Type** | < 0.001 | | |
| I | Ref | Ref | |
| II | 0.303 | 0.023–4.028 | |
| III | 0.187 | 0.021–1.668 | |
| IV | 0.923 | 0.110–7.733 | |
| **T stage by CT scan** | 0.049 | | |
| T1 | Ref | Ref | |
| T2 | 0.405 | 0.099–1.655 | |
| T3 | 0.984 | 0.256–3.786 | |
| T4a | 3.088 | 0.577–16.528 | |
| T4b | 1.466 | 0.465–4.620 | |
| **Serum CEA Level** | 1.178 | 0.467–2.968 | 0.729 |
| **Serum CA19-9 Level** | 4.546 | 1.729–11.954 | 0.004 |
| **N stage by CT scan** | 4.240 | 2.299–7.818 | < 0.001 |

Abbreviations: OR, odd ratio; CI, confidence interval; Ref: referent.
Figure 1: Nomogram for predicting the probability of lymph node metastasis in gastric cancer. There are 7 rows in the nomogram. The behavioral variables are presented in rows 2 to 5, and the points for each variable correspond to the scale in row 1. The points of the seven variables are added to the total points presented on the scale in row 6, which corresponds to the risk predictor of lymph node metastasis in row 7.

Figure 2: Calibration plot of the predictive model from the development cohort (n = 451): The actual probability versus the predicted probability. The reference line represents perfect equality of the predicted probability and the actual incidence of lymph node metastasis.
Figure 3: ROC curve of the predictive model for the validation cohort (n = 186) (ROC curve with an AUC value of 0.894; the cut-off value was set at 0.109). ROC, receiver-operating characteristic ROC; AUC, area under the ROC curve.

Figure 4: Calibration plot of the predictive model from the validation cohort (n = 186): The actual probability versus the predicted probability. The model is sensitive in predicting lymph node metastasis with a low false-negative rate and a high false-positive rate.
recent research. How to balance the risk of LNM and the rate of LNM may be the next target. Finally, the Lauren classification was considered a risk factor for lymph node metastasis. However, there were too many deletions for the Lauren classification in both the development set and the validation set. Thus, the Lauren classification was not included in our research. Thus, our conclusions might need to be validated in the future.

We thought the AUC of the validation set was higher than the C-index from the development set because of the heterogeneity of the development set and the validation set. In our manuscript, we used a group of gastric cancer patients with a solitary lymph node metastasis or without lymph node metastasis. This nomogram model, developed by these groups of patients, is more sensitive to predict lymph node metastasis. However, in the validation group of patients, most of the patients had more than 1 lymph node metastasis, and the rate of the lymph node positive patients was higher than the development set. In addition, these two points may cause the AUC of the validation set to be higher than the C-index from the development set. In addition, we also need more data to validate this nomogram model.

In conclusion, this nomogram model can be used to predict lymph node status in gastric cancer patients. More data are needed to validate and optimize this model.

**MATERIALS AND METHODS**

**Patients**

The prospectively documented gastric cancer database was reviewed for patients who have undergone gastric cancer surgery with a curative intent between 2000 and 2012 at the Sun Yat-sen University Cancer Center (SYSUCC). The criteria for inclusion in this study were as follows:

1. No synchronization tumors;
2. Radical D2 lymphadenectomy was performed, and more than 14 lymph nodes were harvested with a metastatic lymph node number of 0 or 1;
3. Patient did not receive any neoadjuvant therapy, including chemotherapy, radiotherapy, and Chinese traditional medicine;
4. No recurrence cases and gastric remnant cancer; and
5. Complete follow-up data.

A total of 451 patients were included in our study as the development set. Among these, 350 patients (77.6%) were without lymph node metastasis, and 101 patients (22.4%) had solitary lymph node metastasis. The clinicopathological characteristics that were related to the lymph node metastasis are presented in Table 1.

The validation set consisted of patients with histologically proven gastric cancer who underwent a gastrectomy at Sun Yat-sen University Gastrointestinal Hospital (SYSUGIH) to verify the model. The criteria for inclusion in this study were as follows:

1. No synchronization tumors;
2. No neoadjuvant therapy, including chemotherapy, radiotherapy, and Chinese traditional medicine;
3. No recurrence cases and gastric remnant cancer; and
4. The pathological diagnosis of lymph node metastasis was complete.

A total of 186 patients were included in our study for the validation set. Among these, 59 patients (31.7%) were without lymph node metastasis, and 127 patients (68.3%) had lymph node metastasis.

**Follow-up**

The follow-up included an outpatient follow-up, a telephone follow-up, a letter follow-up, a short message platform follow-up and an e-mail follow-up.

**Statistical analysis**

All data were analyzed using the SPSS 20.0 statistical package (SPSS Inc., Chicago, IL, USA) and R version 2.11.1 (The R Foundation for Statistical Computing, Vienna, Austria). The associations between lymph node metastasis and the clinicopathological parameters were analyzed using the chi-square test (or Fisher’s exact test when appropriate). Continuous variables were transformed into an adequate form to fit the proportional hazards and linearity assumptions. Risk factors for lymph node metastasis were studied using a binary logistic regression modeling technique.

A nomogram was developed as a tool for identifying patients at risk for lymph node metastasis, and it provided a graphical representation of the factors, which can be used to calculate the risk of lymph node metastasis for an individual patient by the points associated with each risk factor. The predictive accuracy of the model was graphically displayed using the receiver operating characteristic curve (ROC). The accuracy of the nomogram was then quantified using the area under the curve (AUC) for the validation. The threshold probabilities are arbitrary cutoff points used to classify patients as lymph node metastasis and non-lymph node metastasis. The sensitivity is defined as the probability of the model predicting a patient will have lymph node metastasis given that the patient has lymph node metastasis. The specificity is defined as the probability of the model predicting a patient will not have lymph node metastasis given that the patient does not have lymph node metastasis. Calibration was performed for the constructed nomogram, and the nomogram was internally validated using 1000 repetitions of bootstrap sample corrections and was externally validated by the database from the SYSUGIH. $P$ values less than 0.05 were considered significant.
CONFLICTS OF INTEREST

None.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87–108.
2. Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in China, 2011. Chinese journal of cancer. 2015; 34:502–507.
3. Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology. 2010; 11:439–449.
4. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. The Lancet Oncology. 2006; 7:309–315.
5. An JY, Baik YH, Choi MG, Noh JH, Sohn TS, Kim S. Predictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: analysis of a single institutional experience. Annals of surgery. 2007; 246:749–753.
6. Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, Fujisaki J, Sano T, Yamaguchi T. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric cancer. 2009; 12:148–152.
7. Park JY, Ryu KW, Eom BW, Yoon HM, Kim SJ, Cho SJ, Lee JY, Kim CG, Kook MC, Choi IJ, Nam BH, Kim YW. Proposal of the surgical options for primary tumor control during sentinel node navigation surgery based on the discrepancy between preoperative and postoperative early gastric cancer diagnoses. Annals of surgical oncology. 2014; 21:1123–1129.
8. Mabry H, Giuliano AE. Sentinel node mapping for breast cancer: progress to date and prospects for the future. Surgical oncology clinics of North America. 2007; 16:55–70.
9. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981–22023 AMAROS trial. Annals of surgical oncology. 2010; 17:1854–1861.
10. Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. Journal of clinical oncology. 2011; 29:1479–1487.
11. Takeuchi H, Kitagawa Y. New sentinel node mapping technologies for early gastric cancer. Annals of surgical oncology. 2013; 20:522–532.
12. Feng XY, Wang W, Luo YX, Wu J, Zhou ZW, Li W, Sun XW, Li YF, Xu DZ, Guan YX, Chen S, Zhan YQ, Zhang XS, et al. Comparison of endoscopic ultrasonography and multislice spiral computed tomography for the preoperative staging of gastric cancer - results of a single institution study of 610 Chinese patients. PloS one. 2013; 8:e78846.
13. Hansen J, Becker A, Kluth LA, Rink M, Steuber T, Zacharias M, Briganti A, Fisch M, Graefen M, Chun FK. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation. Urologic oncology. 2015; 33:384 e381–388.
14. Utsumi T, Oka R, Endo T, Yano M, Kamijima S, Kamiya N, Fujimura M, Sekita N, Mikami K, Hiruta N, Suzuki H. External validation and comparison of two nomograms predicting the probability of Gleason sum upgrading between biopsy and radical prostatectomy pathology in two patient populations: a retrospective cohort study. Japanese journal of clinical oncology. 2015; 45:1091–1095.
15. Dingemans SA, de Rooij PD, van der Vuurst de Vries RM, Budel LM, Contant CM and van der Pool AE. Validation of Six Nomograms for Predicting Non-sentinel Lymph Node Metastases in a Dutch Breast Cancer Population. Annals of surgical oncology. 2016; 23:477–481.
16. Chen CY, Hsu JS, Wu DC, Kang WY, Hsieh JS, Jaw TS, Wu MT, Liu GC. Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology. 2007; 242:472–482.
17. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. Journal of clinical oncology. 2007; 25:2107–2116.
18. Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Annals of surgical oncology. 2007; 14:1853–1859.
19. Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, Park do J, Lee HS, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. Journal of gastroenterology and hepatology. 2010; 25:512–518.
20. Lee IH, Lim CH, Park JM, Cho YK, Song KY, Jeon HM, Park CH. Low accuracy of endoscopic ultrasonography for detailed T staging in gastric cancer. World journal of surgical oncology. 2012; 10:190.
21. Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, Niwa H, Kaibe N, Sasaki M, Tomita T, Miwa H, Hirota S. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. European journal of radiology. 2016; 85:989–995.
22. Serrano OK, Love C, Goldman I, Huang K, Ng N, Abraham T, Da Silva R, Friedmann P, Libutti SK,
Kennedy TJ. The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review. Journal of surgical oncology. 2016; 113:640–646.

23. Zhang W. TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chinese journal of cancer. 2014; 33:469–470.

24. Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chinese journal of cancer. 2016; 35:49.